跳至主要内容
临床试验/JPRN-UMIN000015404
JPRN-UMIN000015404已完成未知

The prospective study of the clinical efficacy/adverse event of regorafenib in unresectable metastatic and advanced colorectal cancer - Prediction of the Efficacy/Adverse event of Regorafenib in advanced Colorectal cancer (PEARC study)

Department of Clinical Oncology, Akita University Hospital0 个研究点目标入组 50 人开始时间: 2014年10月10日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. with potent drug affected activity of CYP3A4 or UGT1A9, and with potent drug affected blood concentration of regorafenib. 2. Pregnant female, possibly pregnant females and females feeding babies. 3. with uncontrollable hypertension (systolic >150 mmHg or diastolic >90 mmHg even with hypotensives) 4. with a history of embolism, ischemic heart disease, unstable angina, heart failure or cerebrovascular disease. 5. with severe allergy. 6. Any other patients whom the physician in charge of the study judges to be unsuitable.

研究者

发起方
Department of Clinical Oncology, Akita University Hospital

相似试验